Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | VDR | P11473 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9305625 | 1.00 | ALDH1A1 (0.48) | ALDH1A1CYP2D6CYP3A4TSHRMAPT | |
| SCHEMBL11099885 | 0.83 | ALDH1A1 (0.42) | ALDH1A1CYP2D6CYP3A4TSHRMAPT | |
| SCHEMBL17271955 | 0.83 | LMNA (0.46) | ALDH1A1CYP2D6CYP3A4TSHRMAPT | |
| SCHEMBL5845241 | 0.82 | LMNA (0.64) | ALDH1A1MAPK1LMNASMN1; SMN2RAB9A | |
| SCHEMBL440397 | 0.82 | LMNA (0.64) | ALDH1A1MAPK1LMNASMN1; SMN2RAB9A | |
| SCHEMBL9303799 | 0.82 | PRMT5 (0.53) | ALDH1A1CYP2D6CYP3A4TSHRMAPT | |
| SCHEMBL11102654 | 0.82 | LMNA (0.48) | ALDH1A1CYP2D6CYP3A4TSHRMAPT | |
| SCHEMBL9303794 | 0.82 | PRMT5 (0.53) | ALDH1A1CYP2D6CYP3A4TSHRMAPT | |
| SCHEMBL567428 | 0.82 | LMNA (0.64) | ALDH1A1MAPK1LMNASMN1; SMN2RAB9A | |
| SCHEMBL14094197 | 0.82 | MEN1 (0.36) | ALDH1A1CYP2D6CYP3A4TSHRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5326885-A | Process of preparing enriched enantiomers of glycerol carbonate and derivatives thereof for synthesis of β-blockers | COGNIS, INC. (US) | 1994-07-05 | — | — | US | claimed |
| WO-1993022451-A1 | PROCESS OF PREPARING ENRICHED ENANTIOMERS OF GLYCEROL CARBONATE AND DERIVATIVES THEREOF FOR SYNTHESIS OF β-BLOCKERS | COGNIS, INC. (US) | 1993-11-11 | — | — | WO | claimed |
| EP-3596061-B1 | COMPOUNDS USEFUL IN THE TREATMENT OR PREVENTION OF A PRMT5-MEDIATED DISORDER | ARGONAUT THERAPEUTICS LTD (GB) | 2023-09-06 | — | — | EP | disclosed |
| US-11485731-B2 | Compounds and methods useful in the treatment of a PRMT5-mediated disorder | Argonaut Therapeutics Limited (GB) | 2022-11-01 | — | — | US | disclosed |
| US-20200325128-A1 | COMPOUNDS USEFUL IN THE TREATMENT OR PREVENTION OF A PRMT5-MEDIATED DISORDER | Argonaut Therapeutics Limited (GB) | 2020-10-15 | — | — | US | disclosed |
| WO-2018167269-A1 | COMPOUNDS USEFUL IN THE TREATMENT OR PREVENTION OF A PRMT5-MEDIATED DISORDER | Argonaut Therapeutics Limited (GB) | 2018-09-20 | — | — | WO | disclosed |
| US-20150259470-A1 | LOW-MOLAR-MASS POLYMERS COMPRISING AT LEAST ONE 4-METHYLETHER-1,3-DIOXOLAN-2-ONE END GROUP | BOSTIK SA (FR) | 2015-09-17 | — | — | US | disclosed |
| US-20150259470-A1 | LOW-MOLAR-MASS POLYMERS COMPRISING AT LEAST ONE 4-METHYLETHER-1,3-DIOXOLAN-2-ONE END GROUP | BOSTIK SA (FR) | 2015-09-17 | — | — | US | disclosed |
| WO-2014068250-A1 | LOW-MOLAR-MASS POLYMERS COMPRISING AT LEAST ONE 4-METHYLETHER-1,3-DIOXOLAN-2-ONE END GROUP | BOSTIK SA (FR) | 2014-05-08 | — | — | WO | disclosed |
| US-5326885-A | Process of preparing enriched enantiomers of glycerol carbonate and derivatives thereof for synthesis of β-blockers | COGNIS, INC. (US) | 1994-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11485731-B2 | Compounds and methods useful in the treatment of a PRMT5-mediated disorder | PRMT5, PRMT6, PRMT1 | ALDH1A1 3822/4885CYP2D6 4546/4885CYP3A4 4755/4885 |
| US-20200325128-A1 | COMPOUNDS USEFUL IN THE TREATMENT OR PREVENTION OF A PRMT5-MEDIATED DISORDER | PRMT5, PRMT6, PRMT1 | ALDH1A1 3909/4885CYP2D6 4610/4885CYP3A4 4791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.